Drug Profile


Alternative Names: Cp2TiCl2; MKT 4; Titanocene dichloride

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Medac
  • Class
  • Mechanism of Action Angiogenesis inhibitors; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Apr 2007 Discontinued - Phase-II for Cancer in United Kingdom (IV-infusion)
  • 24 Apr 2007 Discontinued - Phase-II for Cancer in Germany (IV-infusion)
  • 25 May 2000 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top